Cite
HARVARD Citation
Bringhen, S. et al. (2021). Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis. Leukemia research. p. . [Online].